Overview

• A Nature Medicine–published phase 3 study in 820 adults found VER-01 reduced pain by 1.9 points on a 0–10 scale over 12 weeks versus a 1.4-point drop with placebo.
• Participants also reported better sleep and improved physical well-being compared with baseline.
• The treatment was generally well tolerated, with early dizziness, somnolence and nausea most common, and no observed dose escalation, abuse, dependence or withdrawal.
• Experts called the findings clinically relevant but not a paradigm shift, noting potential greater benefit for patients with neuropathic pain features requires further confirmation.
• Germany’s BfArM is evaluating an approval application, and the product could reach the market this year under the brand name Exilby if cleared.